Studies have shown that Staufen protein levels are markedly upregulated in multiple cell and animal models of human neurodegenerative diseases, including those associated with mutations in presenilin 1, and microtubule-associated protein tau, as well as in stroke and myotonic dystrophy (Gandelman et al., 2020). This evidence concerns the gene MAPT and stroke disorder.